Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Illumina Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Illumina Inc ranked in the 24th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 72%. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:
The company's debt burden, as measured by earnings divided by interest payments, is 19.8; that's higher than 82.45% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 13.63% of the free cash flow producing stocks we're observing.
ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.85% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DHR, ICUI, WAT, CDNA, and CNC can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering. Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global next generation sequencing market. The global next generation sequencing
DUBLIN--(BUSINESS WIRE)--The "Cell Analysis Global Market - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The cell analysis global market is expected to reach $33,542.0 million by 2027 growing at a mid-single-digit CAGR from 2020 to 2027. Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is important to understan
The Global mRNA Sequencing Market has witnessed continuous growth in the past few years and may grow further during the forecast period (2020-2025). The assessment provides a 360° view and insights, outlining the key outcomes of the industry, current scenario